Please login to the form below

Not currently logged in
Email:
Password:

hypertension

This page shows the latest hypertension news and features for those working in and with pharma, biotech and healthcare.

Pharma sales help Bayer escape the worst from a bumpy 2017

Pharma sales help Bayer escape the worst from a bumpy 2017

The two brands, along with cancer drugs Xofigo and Stivarga and pulmonary hypertension treatment Adempas, are seen by the company as its key growth brands.

Latest news

  • FDA’s year-end approvals take annual tally to 46 FDA’s year-end approvals take annual tally to 46

    The traditional late flurry of approvals was a bit smaller this year, but included Aerie Pharma’s Rhopressa (netarsudil), a once-daily drug for open-angle glaucoma and ocular hypertension that

  • Amgen hopes its latest Kyprolis trial hits the mark with regulators Amgen hopes its latest Kyprolis trial hits the mark with regulators

    The firm said the most frequently reported treatment-emergent adverse events in either treatment arm of the study were anaemia, diarrhoea, fatigue, hypertension, insomnia and fever.

  • The conundrum of screening The conundrum of screening

    Good examples of screening programmes where the early detection, diagnosis and treatment have favourable outcomes are glaucoma, hypertension and breast cancer, to name a few.

  • EMA clears Bayer's Stivarga for liver cancer EMA clears Bayer's Stivarga for liver cancer

    Stivarga is a key component among a new generation of pharma products - along with cancer drug Xofigo (radium-223 dichloride), anticoagulant Xarelto (rivaroxaban), ophthalmic therapy Eylea (aflibercept) and pulmonary arterial hypertension

  • Biosimilars eat into J&J's Remicade sales Biosimilars eat into J&J's Remicade sales

    This is the first set of financial results for J&J since it closed the acquisition of Swiss biotech Actelion, a specialist in pulmonary arterial hypertension (PAH), on June 16.

More from news
Approximately 14 fully matching, plus 270 partially matching documents found.

Latest Intelligence

  • Reading human behaviour to create a medical future Reading human behaviour to create a medical future

    improve. “Now, we are now at a stage where the biggest causes of morbidity and mortality are diabetes, obesity, CVD and hypertension and autoimmune conditions which require significant self-management, so

  • Tools for the digital world Tools for the digital world

    One study showed that patients with uncontrolled hypertension and diabetes achieved significantly greater reduction in blood pressure (BP) and LDL cholesterol, and were more likely to reach their BP goal, than

  • Proving real-world value Proving real-world value

    Insights reach R&D that ordinarily take years; beta-blockers, for example, found expanded use to control hypertension only after retrospective analysis of four decades of use in heart attack patients.”.

  • Is it time we stopped talking about adherence? Is it time we stopped talking about adherence?

    The EarthWorks has employed this philosophy to develop award-winning patient support programmes in chronic conditions such as asthma and HIV, and rare, complex conditions such as pulmonary arterial hypertension.

  • Tackling the challenge of non-adherence Tackling the challenge of non-adherence

    80% in just five disease areas - asthma, type 2 diabetes, coronary heart disease, hypertension and schizophrenia - would generate cost-savings in excess of £500m a year. ... were able to identify those with uncontrolled hypertension due to medication non

More from intelligence
Approximately 0 fully matching, plus 32 partially matching documents found.

Latest appointments

  • J&J's Jane Griffiths named global head of Actelion J&J's Jane Griffiths named global head of Actelion

    At that point it will gain marketed products that include a trio of pulmonary artery hypertension (PAH) drugs - Tracleer (bosentan), Opsumit (macitentan) and Uptravi (selexipag).

  • New associate director at Packer Forbes New associate director at Packer Forbes

    Prior to this role she was a brand lead at pharma company Actelion where she spent several years on the marketing of hypertension treatment Tracleer (bosentan), during which time she worked

  • Three directors join UK’s MHRA Three directors join UK’s MHRA

    His research has focused on internal medicine, hypertension and cardiovascular risk management, and he established Edinburgh University's Wellcome Trust cardiovascular research initiative and centre for cardiovascular science.

  • Kite Pharma appoints Zelboraf scientist as CMO Kite Pharma appoints Zelboraf scientist as CMO

    Prior to joining Plexxikon, Dr Nolop was VP of clinical research at CoTherix, where he led the development and US approval for Ventavis (iloprost) to treat pulmonary arterial hypertension (PAH).

More from appointments
Approximately 0 fully matching, plus 4 partially matching documents found.

Latest from PMHub

  • 6 Ways to Make MROC’s Rock

    stand on your head, say cheese and record a video of yourself decanting your pills into a box may not yield the best understanding of how hypertension medication is managed at

  • Ageing in China: The Implications for Healthcare

    According to a recent survey, there are 62 million elderly experiencing body pain and 100 million having hypertension.

  • Packer Forbes News May 2015

    To date, her therapeutic experience covers sexual health, mental health, endocrinology, oncology, hypertension and diagnostic medicine.

  • Packer Forbes News January 2016

    year. Amy is looking forward to working on a range of therapy areas including pulmonary arterial hypertension and HIV.

  • 6 things that doctors want

    adherence conditions like hypertension– perhaps by prompting patients to follow the prescription or lifestyle advice.What’ s key is that technology must make the treatment meaningful to patients.

More from PMHub
Approximately 0 fully matching, plus 12 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Quintiles

With a network of more than 27,000 employees conducting business in approximately 100 countries, we have helped develop or commercialize...

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...

Infographics